MX2019004767A - Composiciones dispersables. - Google Patents
Composiciones dispersables.Info
- Publication number
- MX2019004767A MX2019004767A MX2019004767A MX2019004767A MX2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- useful
- dispersible compositions
- dispersible
- rilpivirine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Furan Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621036404 | 2016-10-24 | ||
| PCT/EP2017/077030 WO2018077815A1 (en) | 2016-10-24 | 2017-10-23 | Dispersible compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004767A true MX2019004767A (es) | 2019-07-01 |
Family
ID=60262899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004767A MX2019004767A (es) | 2016-10-24 | 2017-10-23 | Composiciones dispersables. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11065198B2 (https=) |
| EP (2) | EP4248947A3 (https=) |
| JP (2) | JP7197474B2 (https=) |
| KR (2) | KR20190073450A (https=) |
| CN (1) | CN110191704A (https=) |
| CA (1) | CA3039562A1 (https=) |
| DK (1) | DK3528791T3 (https=) |
| ES (1) | ES2970870T3 (https=) |
| FI (1) | FI3528791T3 (https=) |
| HR (1) | HRP20240118T1 (https=) |
| HU (1) | HUE064823T2 (https=) |
| LT (1) | LT3528791T (https=) |
| MA (1) | MA46563B1 (https=) |
| MX (1) | MX2019004767A (https=) |
| PL (1) | PL3528791T3 (https=) |
| PT (1) | PT3528791T (https=) |
| RS (1) | RS65159B1 (https=) |
| SI (1) | SI3528791T1 (https=) |
| SM (1) | SMT202400060T1 (https=) |
| TW (1) | TWI821163B (https=) |
| WO (1) | WO2018077815A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022538338A (ja) * | 2019-07-03 | 2022-09-01 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 |
| CN115397422A (zh) | 2019-11-29 | 2022-11-25 | 西皮欧生命科学有限公司 | 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途 |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| CN114392241B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种利匹韦林片及其制备方法 |
| GB202211231D0 (en) * | 2022-08-02 | 2022-09-14 | Glaxosmithkline Ip No 2 Ltd | Novel formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0181966A1 (en) * | 1984-11-13 | 1986-05-28 | Gist-Brocades N.V. | Compression-coated dispersible tablets |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| KR101140785B1 (ko) | 2002-08-09 | 2012-05-03 | 얀센 파마슈티카 엔.브이. | 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법 |
| ATE508748T1 (de) | 2004-09-02 | 2011-05-15 | Janssen Pharmaceutica Nv | Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril. |
| CA2577288C (en) | 2004-09-02 | 2010-11-30 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| UA92469C2 (en) * | 2004-09-02 | 2010-11-10 | Янссен Фармацевтика Н.В. | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile |
| EP2040671B1 (en) | 2006-06-23 | 2018-01-24 | Janssen Sciences Ireland UC | Aqueous suspensions of tmc278 |
| US20160346198A1 (en) | 2014-02-05 | 2016-12-01 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| WO2015136294A1 (en) * | 2014-03-13 | 2015-09-17 | Cipla Limited | Pharmaceutical composittion comprising rilpivirine |
| CA2949094A1 (en) * | 2014-05-16 | 2015-11-19 | Vivus, Inc. | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use |
-
2017
- 2017-10-23 WO PCT/EP2017/077030 patent/WO2018077815A1/en not_active Ceased
- 2017-10-23 US US16/344,143 patent/US11065198B2/en active Active
- 2017-10-23 CA CA3039562A patent/CA3039562A1/en active Pending
- 2017-10-23 EP EP23169649.3A patent/EP4248947A3/en active Pending
- 2017-10-23 RS RS20240158A patent/RS65159B1/sr unknown
- 2017-10-23 MA MA46563A patent/MA46563B1/fr unknown
- 2017-10-23 MX MX2019004767A patent/MX2019004767A/es unknown
- 2017-10-23 FI FIEP17794275.2T patent/FI3528791T3/fi active
- 2017-10-23 DK DK17794275.2T patent/DK3528791T3/da active
- 2017-10-23 LT LTEPPCT/EP2017/077030T patent/LT3528791T/lt unknown
- 2017-10-23 KR KR1020197014202A patent/KR20190073450A/ko not_active Ceased
- 2017-10-23 SM SM20240060T patent/SMT202400060T1/it unknown
- 2017-10-23 KR KR1020247001197A patent/KR102861006B1/ko active Active
- 2017-10-23 PT PT177942752T patent/PT3528791T/pt unknown
- 2017-10-23 EP EP17794275.2A patent/EP3528791B1/en active Active
- 2017-10-23 CN CN201780065671.8A patent/CN110191704A/zh active Pending
- 2017-10-23 SI SI201731486T patent/SI3528791T1/sl unknown
- 2017-10-23 PL PL17794275.2T patent/PL3528791T3/pl unknown
- 2017-10-23 JP JP2019521720A patent/JP7197474B2/ja active Active
- 2017-10-23 HR HRP20240118TT patent/HRP20240118T1/hr unknown
- 2017-10-23 HU HUE17794275A patent/HUE064823T2/hu unknown
- 2017-10-23 ES ES17794275T patent/ES2970870T3/es active Active
- 2017-10-24 TW TW106136552A patent/TWI821163B/zh active
-
2021
- 2021-06-15 US US17/347,929 patent/US20220008333A1/en not_active Abandoned
-
2022
- 2022-10-14 JP JP2022165319A patent/JP2023011659A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501331A1 (en) | Dispersible compositions | |
| MX2019004767A (es) | Composiciones dispersables. | |
| AU2018285213A1 (en) | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides | |
| NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
| MY192607A (en) | Antiviral beta-amino acid ester phosphodiamide compounds | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| MX388757B (es) | Profármacos de éster alifático antivíricos de tenofovir. | |
| MD4841B1 (ro) | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică | |
| JOP20170135A1 (ar) | مركبات ديازاسبيروألكيل مثيل-إندول | |
| EP4371616A3 (en) | Compositions of obeticholic acid and methods of use | |
| UA114006C2 (xx) | Похідні 5-фенокси-3h-піримідин-4-ону і їхнє застосування як інгібіторів зворотної транскриптази віл | |
| EP3757105A3 (en) | Polycyclic pyridone derivative having integrase inhibitory activity | |
| EP4424374A3 (en) | Crystalline forms of tenofovir alafenamide | |
| WO2017211371A3 (en) | Calr and jak2 vaccine compositions | |
| WO2015017393A3 (en) | Piperazine derivatives as hiv protease inhibitors | |
| JOP20170029B1 (ar) | C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1 | |
| EP4512816A3 (en) | Tlr7 agonists | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| WO2015086738A3 (en) | Hiv vaccine | |
| MA40496A (fr) | Capsacinoïdes et leurs utilisations en tant que médicaments | |
| WO2014210082A3 (en) | Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association | |
| PH12019501206A1 (en) | Medical skin external preparation | |
| WO2014140680A8 (en) | Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection | |
| WO2019212427A3 (en) | Compositions comprising erdosteine and ascorbic acid | |
| HK1261812A1 (en) | Methods and compositions for rna-guided treatment of hiv infection |